L1000 fireworks display (L1000FWD) provides interactive visualization of over 16,000 drug and small-molecule induced gene expression signatures. It enables overlaying various drug attributes such as MOA and clinical usages extracted from the EMR/EHR.
In a major change of strategy, the new head of GlaxoSmithKline, Andrew Witty, has told the Guardian he will slash prices on all medicines in the poorest countries, give back profits to be spent on hospitals and clinics and – most ground-breaking of all – share knowledge about potential drugs that are currently protected by patents. Witty says he believes drug companies have an obligation to help the poor get treatment. He challenges other pharmaceutical giants to follow his lead.
In the second part of a special report, Nina Lakhani exposes how survivors of the 1984 Bhopal gas disaster became unwitting guinea pigs in studies funded by Western drug companies. Secret reports seen by The Independent reveal that drug trials funded by western pharmaceutical firms at the Indian hospital set up for survivors of the Bhopal disaster violated international ethical standards and could have put patients at risk.
Human enhancement and the future of work summarises technological advancements that could dramatically change how people work over the next decade. These technologies, such as cognitive enhancing drugs, bionic limbs and retinal implants, affect various human capacities such as memory, hearing and mobility. The report explores how, although human enhancement technologies might aid society, their use could raise serious ethical, philosophical, regulatory and economic issues that will need further consideration.
R. Lalonde, und R. Willke. Clinical pharmacology and therapeutics, 90 (6):
761-3(Dezember 2011)6577<m:linebreak></m:linebreak>JID: 0372741; 0 (Drugs, Generic); ppublish;<m:linebreak></m:linebreak>CER.
B. Gómez, M. Placeres, und N. Riba. Medicina clínica, 132 (8):
322-7(März 2009)4931<m:linebreak></m:linebreak>JID: 0376377; 2008/08/04 received; 2008/10/17 accepted; 2009/02/15 aheadofprint; ppublish;<m:linebreak></m:linebreak>Polítiques de recerca.
J. Millar, und V. Burke. Journal of clinical pharmacy and therapeutics, 27 (5):
329-33(Oktober 2002)3454<m:linebreak></m:linebreak>Tests d'equivalència.
J. Quinlan, B. Gaydos, J. Maca, und M. Krams. Clinical trials (London, England), 7 (2):
167-73(April 2010)5547<br/>JID: 101197451; 2010/03/25 aheadofprint; ppublish;<br/><br/>Disseny; Dissenys adaptatius.